EA200500934A1 - Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний - Google Patents

Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний

Info

Publication number
EA200500934A1
EA200500934A1 EA200500934A EA200500934A EA200500934A1 EA 200500934 A1 EA200500934 A1 EA 200500934A1 EA 200500934 A EA200500934 A EA 200500934A EA 200500934 A EA200500934 A EA 200500934A EA 200500934 A1 EA200500934 A1 EA 200500934A1
Authority
EA
Eurasian Patent Office
Prior art keywords
activity
methods
inflammatory diseases
neurodegenerative
multiple lines
Prior art date
Application number
EA200500934A
Other languages
English (en)
Inventor
Анна Мэрони
Кевин М. Уолтон
Крэйг А. Дайонн
Никола Нефф
Эрнест мл. Найт
Марси А. Гликсман
Original Assignee
Сефалон, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сефалон, Инк. filed Critical Сефалон, Инк.
Publication of EA200500934A1 publication Critical patent/EA200500934A1/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Abstract

Настоящее изобретения относится к соединениям формулымодулирующим активность киназного белка множественных линий (MLK), которые либо повышают выживаемость клеток, либо стимулируют гибель клеток, и к способам лечения нейродегенеративных и/или воспалительных заболеваний с помощью указанных соединений.
EA200500934A 1998-08-26 1999-08-18 Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний EA200500934A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9798098P 1998-08-26 1998-08-26

Publications (1)

Publication Number Publication Date
EA200500934A1 true EA200500934A1 (ru) 2006-04-28

Family

ID=22266038

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200500934A EA200500934A1 (ru) 1998-08-26 1999-08-18 Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
EA200100278A EA006648B1 (ru) 1998-08-26 1999-08-18 Способы модулирования киназных белков множественных линий и скрининга соединений, которые модулируют киназные белки множественных линий

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA200100278A EA006648B1 (ru) 1998-08-26 1999-08-18 Способы модулирования киназных белков множественных линий и скрининга соединений, которые модулируют киназные белки множественных линий

Country Status (25)

Country Link
EP (1) EP1105728B1 (ru)
JP (1) JP2002523780A (ru)
KR (1) KR100700028B1 (ru)
CN (3) CN1879617A (ru)
AT (1) ATE293254T1 (ru)
AU (1) AU765637B2 (ru)
BG (1) BG105360A (ru)
BR (1) BR9913190A (ru)
CA (1) CA2339539A1 (ru)
CZ (1) CZ2001701A3 (ru)
DE (1) DE69924738T2 (ru)
DK (1) DK1105728T3 (ru)
EA (2) EA200500934A1 (ru)
ES (1) ES2241316T3 (ru)
HK (1) HK1037722A1 (ru)
HU (1) HUP0103079A3 (ru)
NO (1) NO20010389L (ru)
NZ (1) NZ509612A (ru)
PL (1) PL346246A1 (ru)
PT (1) PT1105728E (ru)
SK (1) SK2542001A3 (ru)
TR (2) TR200100589T2 (ru)
UA (1) UA74772C2 (ru)
WO (1) WO2000013015A1 (ru)
ZA (1) ZA200100835B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US7122679B2 (en) * 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof
IL154311A0 (en) * 2000-08-11 2003-09-17 Cephalon Inc Modulating multiple lineage kinase proteins
AR035971A1 (es) 2001-05-16 2004-07-28 Cephalon Inc Metodos para el tratamiento y la prevencion del dolor
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP2003052395A (ja) * 2001-08-09 2003-02-25 Japan Tissue Engineering:Kk 移植適正判定方法
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
CA2711585A1 (en) * 2008-02-04 2009-08-13 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
US20100056609A1 (en) * 2008-08-26 2010-03-04 Washington University Methods and compositions for inhibition of axonal degeneration by modulation of the dlk/jnk pathway
AU2009308293B2 (en) * 2008-10-22 2015-02-05 Genentech, Inc. Modulation of axon degeneration
AU2015202365B2 (en) * 2008-10-22 2016-11-24 Genentech, Inc. Modulation of axon degeneration
CN104043126A (zh) * 2009-10-22 2014-09-17 霍夫曼-拉罗奇有限公司 轴突变性的调节
ES2385157B1 (es) * 2010-02-25 2013-07-08 Universidad Del País Vasco Compuestos para el tratamiento de alzheimer.
EP2852388A4 (en) 2012-05-23 2016-01-13 Univ Johns Hopkins COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
CN109060472A (zh) * 2018-07-20 2018-12-21 上海市农业科学院 一种适于荧光染色的草菇菌褶组织切片的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5475110A (en) * 1994-10-14 1995-12-12 Cephalon, Inc. Fused Pyrrolocarbazoles
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US6811992B1 (en) * 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions

Also Published As

Publication number Publication date
CN1589788A (zh) 2005-03-09
EP1105728A1 (en) 2001-06-13
SK2542001A3 (en) 2002-06-04
DE69924738T2 (de) 2006-03-02
NZ509612A (en) 2003-10-31
ZA200100835B (en) 2002-06-26
BR9913190A (pt) 2001-12-11
AU5679399A (en) 2000-03-21
CZ2001701A3 (cs) 2002-04-17
HK1037722A1 (en) 2002-02-15
EA200100278A1 (ru) 2002-06-27
DE69924738D1 (de) 2005-05-19
ES2241316T3 (es) 2005-10-16
DK1105728T3 (da) 2005-08-08
ATE293254T1 (de) 2005-04-15
NO20010389L (no) 2001-04-02
CN1206535C (zh) 2005-06-15
CN1879617A (zh) 2006-12-20
HUP0103079A2 (hu) 2001-12-28
HUP0103079A3 (en) 2004-03-01
TR200400635T2 (tr) 2005-10-21
AU765637B2 (en) 2003-09-25
EA006648B1 (ru) 2006-02-24
NO20010389D0 (no) 2001-01-23
WO2000013015A1 (en) 2000-03-09
UA74772C2 (en) 2006-02-15
EP1105728B1 (en) 2005-04-13
KR20010103573A (ko) 2001-11-23
CN1314999A (zh) 2001-09-26
JP2002523780A (ja) 2002-07-30
PL346246A1 (en) 2002-01-28
PT1105728E (pt) 2005-07-29
KR100700028B1 (ko) 2007-03-27
TR200100589T2 (tr) 2001-07-23
CA2339539A1 (en) 2000-03-09
WO2000013015A8 (en) 2000-05-11
BG105360A (bg) 2001-10-31

Similar Documents

Publication Publication Date Title
ATE397621T1 (de) Hemmer der interaktion zwischen p53 und mdm2
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
EA200500856A1 (ru) Новые химические соединения
PT1153024E (pt) 2-amino-6-anilino-purinas e sua utilizacao como medicamentos
EA200001224A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
TNSN05045A1 (en) Indole or benzimidazole derivatives for modulating ikappab kinase
WO2003093297A3 (en) Protein kinase modulators and methods of use
EA200870048A1 (ru) ГЕТЕРОАРИЛ-ЗЕМЕЩЕННЫЕ ПИРРОЛО[2,3-b]ПИРИДИНЫ И ПИРРОЛО[2,3-b]ПИРИМИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
ATE406170T1 (de) Kontrolle des proteinspiegels in eukaryotischen organismen
ATE279181T1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
ATE411805T1 (de) Organo-phosphorverbindungen zur aktivierung von gamma/delta-t-zellen
ATE222119T1 (de) Verwendung von erythropoietin zur behandlung von multiple myelom
DE69823493D1 (de) Tetrahydropyridoverbindungen
ATE128128T1 (de) Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
EA200300442A1 (ru) Способы и композиции для лечения воспалительных заболеваний
EP1254260A4 (en) METHODS FOR DIAGNOSING AND TREATING A HEART DISEASE
ATE73995T1 (de) Verwendung von penicillamin zur behandlung von immunmangelkrankheiten.
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
DE60029463D1 (de) Behandlung von dyskinesie
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen